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To establish if the use of early computed tomography 
(CT) coronary angiography improves one year clinical 
outcomes in patients presenting to the emergency 
department with acute chest pain and at intermediate 





37 hospitals in the UK.
PARTICIPANTS
Adults with suspected or a provisional diagnosis of 
acute coronary syndrome and one or more of previous 
coronary heart disease, raised levels of cardiac 
troponin, or abnormal electrocardiogram.
INTERVENTIONS
Early CT coronary angiography and standard of care 
compared with standard of care only.
MAIN OUTCOME MEASURES
Primary endpoint was all cause death or subsequent 
type 1 or 4b myocardial infarction at one year.
RESULTS
Between 23 March 2015 and 27 June 2019, 
1748 participants (mean age 62 years (standard 
deviation 13), 64% men, mean global registry of 
acute coronary events (GRACE) score 115 (standard 
deviation 35)) were randomised to receive early CT 
coronary angiography (n=877) or standard of care 
only (n=871). Median time from randomisation to CT 
coronary angiography was 4.2 (interquartile range 
1.6-21.6) hours. The primary endpoint occurred in 
51 (5.8%) participants randomised to CT coronary 
angiography and 53 (6.1%) participants who received 
standard of care only (adjusted hazard ratio 0.91 
(95% confidence interval 0.62 to 1.35), P=0.65). 
Invasive coronary angiography was performed in 
474 (54.0%) participants randomised to CT coronary 
angiography and 530 (60.8%) participants who 
received standard of care only (adjusted hazard ratio 
0.81 (0.72 to 0.92), P=0.001). There were no overall 
differences in coronary revascularisation, use of drug 
treatment for acute coronary syndrome, or subsequent 
preventive treatments between the two groups. 
Early CT coronary angiography was associated with a 
slightly longer time in hospital (median increase 0.21 
(95% confidence interval 0.05 to 0.40) days from a 
median hospital stay of 2.0 to 2.2 days).
CONCLUSIONS
In intermediate risk patients with acute chest pain and 
suspected acute coronary syndrome, early CT coronary 
angiography did not alter overall coronary therapeutic 
interventions or one year clinical outcomes, but 
reduced rates of invasive angiography while modestly 
increasing length of hospital stay. These findings 
do not support the routine use of early CT coronary 
angiography in intermediate risk patients with acute 




Chest pain is one of the commonest complaints in 
patients presenting to the emergency department.1  2 
These patients are evaluated for acute coronary 
syndrome with urgent diagnostic investigation so that 
those with acute myocardial infarction or at risk of acute 
myocardial infarction receive appropriate treatment 
promptly. Lack of clarity on the optimal diagnostic 
pathways, however, has led to the development of 
risk scores and the use of numerous functional and 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
In stable chest pain, randomised controlled trials have shown that CT coronary 
angiography increases the diagnosis of coronary artery disease, resulting in 
more prescriptions of preventive treatments (aspirin and statins), more coronary 
revascularisation, and lower rates of subsequent death from coronary heart 
disease or non-fatal myocardial infarction
In patients presenting with acute chest pain, no definitive evidence exists that 
the use of CT coronary angiography affects clinical outcomes, although its use 
has been associated with shorter lengths of stay and increases in the use of 
invasive angiography and coronary revascularisation in those at very low risk
Recent international guidelines have suggested that CT coronary angiography might 
be considered to investigate underlying coronary artery disease in intermediate risk 
patients with acute chest pain although the benefits of this strategy are unknown
WHAT THIS STUDY ADDS
In intermediate risk patients with suspected acute coronary syndrome, early CT 
coronary angiography reduced the subsequent use of invasive angiography or 
testing for ischaemia compared with those receiving standard of care only
Early CT coronary angiography did not change the overall frequency of acute or 
preventive treatments or alter subsequent clinical events in intermediate risk 
patients presenting to the emergency department with acute chest pain
The findings do not support the routine use of early CT coronary angiography in 
all intermediate risk patients with acute chest pain
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anatomical testing options to investigate for underlying 
coronary artery disease.3-7 Recent guidelines have 
proposed that patients at low or intermediate risk of 
coronary artery disease should undergo observation 
and further testing if acute coronary syndrome is 
suspected.5-7
Several trials have explored the role of computed 
tomography (CT) coronary angiography in low risk 
patients presenting to the emergency department with 
chest pain.8-11 The trials showed that CT coronary 
angiography increased rates of discharge from hospital 
and shortened length of stay compared with usual 
care. These findings are likely to apply only where 
usual care for patients at low risk involves high rates 
of admission and investigation. Participants were 
at low risk of coronary heart disease (<10%) and 
consequently had low rates of cardiovascular events 
(0.1-0.8%), leading some to suggest that non-invasive 
testing was unnecessary and only clinical evaluation 
was required.12 13
Although recommended in guidelines5-7 as a potential 
strategy for subsequent investigation, the use of early 
CT coronary angiography in patients presenting with 
acute chest pain, who are at intermediate risk of acute 
coronary syndrome and subsequent clinical events, 
has not been investigated or established. This strategy 
could identify patients who would benefit from more 
rapid and appropriate therapeutic interventions, thus 
improving clinical outcomes.14 15 In those patients 
without disease, CT coronary angiography might 
reduce the need for invasive coronary angiography, 
shorten hospital stay, and avoid repeated admissions 
to hospital. If CT coronary angiography does not 
influence investigations, treatments, and outcomes 
of patients, however, it might increase the cost and 
risk without any clinical benefit. Our trial aimed to 
investigate the effect of early CT coronary angiography 
on the management and outcome of patients with 
suspected or a provisional diagnosis of acute coronary 
syndrome, presenting to the emergency department.
Methods
Trial design
We performed a prospective, randomised, open, blinded 
endpoint, parallel group clinical effectiveness trial in 
37 hospitals across the UK. The trial protocol has been 
reported previously.16
Participants and randomisation
From March 2015 to June 2019, adults with symptoms 
of suspected acute coronary syndrome or those 
with a provisional diagnosis of acute coronary 
syndrome and one or more of previous coronary 
heart disease, raised levels of cardiac troponin, or 
abnormal electrocardiogram (ECG), were recruited 
in the emergency department or hospital admission 
facilities. Table S1 lists the full eligibility criteria. 
Written informed consent was provided by all 
participants who were recruited early after admission 
to hospital and randomised 1:1, grouped by site, and 
with variable block sizes (4-8), to early CT coronary 
angiography with standard of care or standard of care 
only, with a web based randomisation service to ensure 
that allocation to the group was concealed.
Trial intervention
ECG gated calcium score and contrast enhanced 
CT coronary angiograms were conducted with ≥64 
slice scanners. All centres were encouraged to use 
techniques to reduce radiation and heart rate, and 
to use sublingual glyceryl trinitrate. CT coronary 
angiograms were reported according to the Society 
of Cardiovascular CT guidelines17 and the American 
Heart Association coronary artery segment model.18 
Severity of disease was categorised as no coronary 
artery disease (cross sectional stenosis <10%), mild 
non-obstructive disease (cross sectional stenosis 
10-49%), moderate non-obstructive disease (cross 
sectional stenosis 50-70%), or obstructive coronary 
artery disease (cross sectional stenosis >70% or >50% 
in the left main stem). Standard of care was at the 
discretion of the attending clinician although guidance 
on treatment based on the CT coronary angiogram 
results was provided to all sites (table S2).
Outcomes
An independent clinical endpoint committee, blinded 
to the trial intervention, adjudicated the trial primary 
outcomes. The primary endpoint was time to the first 
event of all cause death or subsequent non-fatal type 1 
(spontaneous) or type 4b (related to stent thrombosis) 
myocardial infarction at one year. Myocardial 
infarction was defined according to the 2012 universal 
definition of myocardial infarction.19 Key secondary 
endpoints were cause of death (coronary heart disease 
or cardiovascular death) and subsequent myocardial 
infarction. Table S3 describes the trial endpoints. 
Several changes were made to the trial protocol, 
including refining the secondary endpoints during 
the trial (table S4). The final and most substantial 
changes were made to align the endpoints with the 
SCOT-HEART (Scottish Computed Tomography of the 
HEART) trial to allow direct comparisons (protocol 
version 7, 24 February 2020).14 15
Study power and sample size
The original sample size calculation was estimated 
from a one year death or subsequent myocardial 
infarction rate of about 20%.20 At 90% power and a two 
sided P value of <0.05, 2424 evaluable patients were 
required to detect a reduction in death or subsequent 
myocardial infarction from 20% to 15% at one year. 
After review of the first 716 participants, the overall 
event rate was 6.8% (95% confidence interval 5.2% 
to 8.9%). Given this lower than anticipated 12 month 
event rate and the much slower rates of recruitment, 
we consulted with the trial funder and trial steering 
committee and recalculated the sample size, with 
blinded data, to 1735 participants to detect a 3.4% 
absolute risk reduction at a revised primary event 
rate of 6.8% with 80% power and a two sided P value 
<0.05. These reductions in relative effect size have been 
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reported in previous meta-analyses of randomised 
controlled trials of low risk patients presenting to the 
emergency department.11
Statistical analysis
The trial was reported on an intention to treat basis. 
Descriptive data are presented as number (percentage), 
mean (standard deviation), or median (interquartile 
range). The primary outcome was defined as time to the 
first event of all cause death or subsequent non-fatal 
myocardial infarction type 1 or 4b and was analysed 
with Cox proportional hazards regression adjusted for 
study site (used to stratify the randomisation), global 
registry of acute coronary events (GRACE) score,21 
and previous coronary heart disease. Study site was 
included as a random effect and GRACE score with 
a restricted cubic spline. For patients who left the 
trial before reaching the primary outcome, time was 
censored at the last contact date. 
Secondary outcomes were analysed with Cox 
proportional hazards regression for time-to-event 
outcomes and logistic regression for binary outcomes, 
and proportional odds logistic regression for ordinal 
outcomes, adjusted in the same way as the primary 
outcome. For the primary outcome and key secondary 
outcomes, we used the fixed sequence method to 
test for significance; statistical significance was if 
the outcome, and all prior outcomes listed, had a 
two sided P value of <0.05.22 Subgroup analyses 
were performed on the primary outcome for age, 
sex, GRACE score, previous coronary heart disease, 
raised levels of cardiac troponin, abnormal ECG, and 
onsite invasive coronary angiography facilities, with 
treatment-subgroup interaction in the Cox model. The 
proportional hazards assumption was checked for 
the time-to-event outcomes, and we found evidence 
of non-proportional hazards only for the outcome of 
non-invasive coronary artery disease or myocardial 
ischaemia testing. The analysis was performed with 
SAS software (version 9.4, SAS System for Windows).
Patient and public involvement
The trial team liaised with members of the Sheffield 
Emergency Care Forum (a patient and public 
representative group that provides independent advice 
on emergency care related research) during the grant 
application where they reviewed the proposal and 
provided advice on study design, patient procedures, 
and ethical issues, which helped inform the final 
submission and subsequent study design. The forum 
was also consulted during the development of the trial 
information (patient information letters, consents, 
general practitioner letter), and the documents were 
amended to incorporate their feedback, which helped 
improve the usability of the documents. During trial 
delivery, patient representatives participated in the 
trial steering committee and were involved in the 
oversight of the trial throughout its duration. The 
forum provided valuable feedback about the patient 
perspective throughout the trial, which helped guide 
the decision making of the trial team. The Sheffield 
Emergency Care Forum helped develop the plain 
English summary for the final funder report. Members 
of the forum will help develop material to allow us to 
disseminate the trial findings to the public.
Results
Participants
Between 23 March 2015 and 27 June 2019, we recruited 
1749 patients, with 1748 participants available for 
analysis (fig 1). Recruitment stopped when the revised 
recruitment target was reached in June 2019, and the trial 
ended when the planned follow-up was subsequently 
completed in July 2020. The mean age of participants 
was 61.6 (12.6) years, and 1114 (64%) were men. 
At recruitment, 601 (34%) participants had previous 
coronary heart disease, 1004 (57%) had raised levels 
of cardiac troponin, and 1064 (61%) had an abnormal 
ECG. Chest pain was the primary complaint in 1549 
(89%) participants, with 857 (49%) diagnosed as having 
an acute coronary syndrome (myocardial infarction or 
unstable angina) at discharge from their index admission 
to hospital (table S5). The mean GRACE score was 115 
(35) with 410 (23%) participants having a GRACE score 
>140. Baseline characteristics and follow-up were similar 
for the two groups (table 1 and fig 1).
Intervention
Of those patients randomised to CT coronary 
angiography, 767 (87.5%) underwent CT coronary 
angiography; table S6 provides the reasons for non-
adherence. Median time from randomisation to CT 
coronary angiography was 4.2 (interquartile range 
1.6-21.6) hours (fig S1). The CT coronary angiography 
scan was of diagnostic quality in 700 (91.3%) 
patients, with a median effective radiation dose of 
5.8 (3.5-10.3) mSv (0.026 mSv/mGy cm conversion 
factor) and was associated with four related adverse 
events (one readmission with a possibly related non-
cardiac condition and three non-serious adverse 
events related to the intravenous cannula). In the 
standard of care arm, 48 (5.5%) participants had a CT 
coronary angiogram within 30 days of randomisation. 
CT coronary angiography identified normal coronary 
arteries in 178 (23%) patients, non-obstructive disease 
in 222 (29%), and obstructive disease in 359 (47%) 
(table 2).
Primary and key secondary outcomes
The primary outcome of all cause death or non-fatal 
myocardial infarction (type 1 or 4b) at one year occurred 
in 51 (5.8%) of the 877 participants in the early CT 
coronary angiography arm and in 53 (6.1%) of the 
871 participants in the standard of care arm (adjusted 
hazard ratio 0.91 (95% confidence interval 0.62 to 
1.35), P=0.65; fig 2 and table 3). For the prespecified 
subgroup analysis for the primary outcome, we found 
no significant heterogeneity for any comparison (fig 3). 
We found no evidence of a difference between allocated 
treatment arms for any of the key secondary outcomes 
(table 3). Other clinical outcomes (death from coronary 
heart disease or subsequent myocardial infarction type 
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1 or 4b; subsequent myocardial infarction type 1 or 
4b; and non-cardiovascular death) were also similar 
(table S7).
Processes of care and other outcomes
Satisfaction of participants (rated excellent or very 
good on a five point Likert scale) was higher in the early 
CT coronary angiography arm than in the standard of 
care arm (adjusted odds ratio 1.25 (95% confidence 
interval 1.02 to 1.53), P=0.03; table 4). The attending 
clinician reported increased diagnostic certainty after 
CT coronary angiography: mean increase of 1.4 (2.2) 
on a 0-10 scale (from 7.1 to 8.5, with 10 being most 
certain).
Fewer participants in the CT coronary angiography 
arm received invasive coronary angiography: 
474 (54.0%) compared with 530 (60.8%) in the 
standard of care arm (adjusted hazard ratio 0.81 
(95% confidence interval 0.72 to 0.92), P=0.001; 
table 5 and fig 4). Despite fewer invasive coronary 
angiograms in the CT coronary angiography arm, 
we found no evidence of a difference in the rates 
of coronary revascularisation by group (adjusted 
hazard ratio 1.03 (0.87 to 1.21), P=0.76; table 5 and 
fig 4). In a post hoc analysis, subsequent rates of 
non-invasive testing for coronary artery disease and 
myocardial ischaemia were lower in the CT coronary 
angiography arm: 170 (19.4%) compared with 228 
(26.2%) in the standard of care arm (adjusted hazard 
ratio 0.66, 0.54 to 0.81, P<0.001), although for other 
cardiac investigations (echocardiography and rhythm 
monitoring) no evidence of a difference was found 
(adjusted hazard ratio 0.92, 0.81 to 1.04, P=0.19; 
table 5 and fig 5).
Drug treatments for acute coronary syndrome were 
prescribed in hospital for 595 (67.8%) participants in 
the CT coronary angiography arm and in 580 (66.6%) 
in the standard of care arm (adjusted odds ratio 1.06 
(95% confidence interval 0.85 to 1.32), P=0.63). 
At hospital discharge, the change in prescription 
for preventive treatments was similar: 554 (63.2%) 
participants in the CT coronary angiography arm 
compared with 539 (61.9%) in the standard of care 
arm (1.07 (0.87 to 1.32), P=0.52, table 4).
Median length of hospital stay was longer in the CT 
coronary angiography arm: 2.2 (interquartile range 
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1.1-4.1) days compared with 2.0 (1.0-3.8) days in the 
standard of care arm (Hodges-Lehmann estimator of 
location shift, 0.21 (95% confidence interval 0.05 
to 0.40) days; P=0.009). We found no difference in 
the discharge diagnosis of acute coronary syndrome 
(myocardial infarction or unstable angina): 50.2% 
in the CT coronary angiography arm compared with 
47.9% in the standard of care only arm (table S5). 
Chest pain symptoms, re-attendance at hospital, 
and quality of life at one year were unchanged by 




This multicentre, randomised controlled trial aimed to 
establish the clinical effectiveness of early CT coronary 
angiography in the management and outcome of 
patients presenting to the emergency department 
with suspected acute coronary syndrome or with a 
provisional diagnosis of acute coronary syndrome. We 
found no evidence that CT coronary angiography had 
an effect on the one year rate of death or subsequent 
non-fatal myocardial infarction. Also, no evidence of 
benefit for any of the prespecified subgroup analyses or 
key secondary outcomes, or length of stay, was found. 
We conclude that the routine use of early CT coronary 
angiography is not an appropriate strategy to reduce 
one year clinical events in intermediate risk patients 
with acute chest pain.
We recruited a large population of patients with 
suspected acute coronary syndrome or those with a 
provisional diagnosis of acute coronary syndrome who 
had a spectrum of risk, reflected in the range of GRACE 
scores. Our trial population was equally composed 
of those who had or did not have a final diagnosis 
of acute coronary syndrome, and those who had or 
did not have obstructive coronary artery disease, a 
population that was truly representative of patients 
with an intermediate level of risk. 
Table 1 | Baseline patient characteristics
CT coronary angiography 
and standard of care Standard of care only Overall
No of participants 877 871 1748
Age (mean (SD)) 61.9 (12.2) 61.2 (13.0) 61.6 (12.6)
Male sex 564 (64) 550 (63) 1114 (64)
Previous coronary heart disease 302 (34) 299 (34) 601 (34)
Raised levels of cardiac troponin 492 (56) 512 (59) 1004 (57)
Abnormal electrocardiogram 549 (63) 515 (59) 1064 (61)
GRACE score:
 Mean (SD) 115 (36) 114 (34) 115 (35)
 Low risk (<109) 390 (44) 384 (44) 774 (44)
 Intermediate risk (109-140) 268 (31) 296 (34) 564 (32)
 High risk (>140) 219 (25) 191 (22) 410 (23)
Recruited at hospital with onsite invasive coronary 
angiography facilities
644 (73) 641 (74) 1285 (74)
Presenting complaint:*
 Chest pain 776 (89) 773 (89) 1549 (89)
 Shortness of breath 35 (4) 31 (4) 66 (4)
 Palpitation 17 (2) 15 (2) 32 (2)
 Collapse 10 (1) 10 (1) 20 (1)
 Other 38 (4) 42 (5) 80 (5)
Cardiovascular risk factors:
 Diabetes mellitus 153 (17) 165 (19) 318 (18)
 Hypertension 413 (47) 404 (46) 817 (47)
 Hyperlipidaemia 358 (41) 336 (39) 694 (40)
 Current or ex-smoker 530 (60) 531 (61) 1061 (61)
 Family history† 269 (31) 270 (31) 539 (31)
Medical history:
 Myocardial infarction‡ 180 (21) 171 (20) 351 (20)
 Previous coronary angiography 222 (25) 214 (25) 436 (25)
 Previous PCI§ 115 (13) 123 (14) 238 (14)
 Previous CABG surgery¶ 52 (6) 48 (6) 100 (6)
 Cerebrovascular disease 35 (4) 38 (4) 73 (4)
 Peripheral vascular disease 27 (3) 28 (3) 55 (3)
Preventive treatment:
 Aspirin treatment 203 (23) 212 (24) 415 (24)
 Statin treatment 283 (32) 298 (34) 581 (33)
 ACE inhibitor or ARB treatment 217 (25) 216 (25) 433 (25)
Data are number (%) unless stated otherwise. 
CT=computed tomography; GRACE=global registry of acute coronary events; PCI=percutaneous coronary intervention; CABG=coronary artery bypass graft; 
ACE=angiotensin converting enzyme; ARB=angiotensin receptor blocker; SD=standard deviation.
*Missing data: one participant in CT coronary angiography and standard of care arm.
†Missing data: four participants in CT coronary angiography and standard of care arm and one participant in standard of care only arm.
‡Missing data: one participant in standard of care only arm. 
§Missing data: three participants in standard of care only arm. 
¶Missing data: one participant in standard of care only arm.
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The use of early CT coronary angiography had 
no effect on rates of treatments for acute coronary 
syndrome, with similar rates of use of drug treatment for 
acute coronary syndrome, coronary revascularisation, 
and preventive treatments at discharge from hospital. 
These findings are likely to reflect the high sensitivity 
of current clinical assessment, combining testing 
for cardiac troponin with a 12 lead ECG. Current 
practice therefore provided limited opportunity for 
CT coronary angiography to identify patients with 
unrecognised acute coronary syndrome caused by 
coronary heart disease. Moreover, for CT coronary 
angiography to improve adverse coronary events, 
it would need to alter the management of patients. 
These changes have been seen in previous studies 
of patients with stable chest pain where CT coronary 
angiography improved the detection of unrecognised 
coronary artery disease, increasing the use of 
preventive treatments and coronary revascularisation. 
These changes in management were associated with 
reduced rates of subsequent death from coronary 
heart disease or non-fatal myocardial infarction.14 
15 In our population of patients with acute chest 
pain and relatively high rates of invasive coronary 
angiography and coronary revascularisation, we 
found no such changes. We might have recruited 
too many patients who were at high risk of disease 
and therefore were candidates for inpatient invasive 
coronary angiography. However, more than three 
quarters of participants had a low or intermediate 
GRACE risk score, and less than 50% had obstructive 
coronary artery disease. In our prespecified subgroup 
analyses, no evidence of heterogeneity of effect for 
the primary outcome according to the level of risk was 
found. These subgroups are the focus of contemporary 
guidelines,5-7 which attempt to define intermediate 
risk groups suitable for observation and additional 
testing, including CT coronary angiography. We could 
not show an effect of CT coronary angiography on one 
year clinical outcomes in any of these subgroups or 
risk categories.
Benefits of early CT coronary angiography
Early CT coronary angiography was associated with 
some benefits. Patients valued the use of CT coronary 
angiography, possibly reflecting a quicker evaluation 
of their clinical condition and the enhanced diagnostic 
certainty of the attending clinician. CT coronary 
angiography was also associated with a reduction 
in invasive coronary angiography, contrasting with 
previous trials of acute chest pain where CT coronary 
angiography was associated with increased rates of 
invasive angiography.8-11 23 This disparity likely reflects 
differences in trial populations, especially the baseline 
risk and prevalence of coronary heart disease. 
Table 2 | Clinical characteristics and subsequent management according to CT coronary angiogram findings in 






No of participants 178 222 359
Age (mean (SD)) 54.9 (12.4) 63.3 (11.4) 64.0 (11.6)
Male sex 67 (38) 132 (59) 279 (78)
Previous coronary heart disease 27 (15) 85 (38) 144 (40)
Raised levels of cardiac troponin 69 (39) 104 (47) 249 (69)
Abnormal electrocardiogram 114 (64) 129 (58) 231 (64)
GRACE score:
 Low risk (<109) 125 (70) 107 (48) 108 (30)
 Intermediate risk (109-140) 34 (19) 64 (29) 141 (39)
 High risk (>140) 19 (11) 51 (23) 110 (31)
Onsite coronary angiography 139 (78) 163 (73) 254 (71)
Invasive coronary angiogram performed 25 (14) 83 (37) 289 (81)
Acute coronary syndrome treatment* 105 (59) 145 (65) 271 (75)
Coronary revascularisation 7 (4) 26 (12) 222 (62)
Preventive treatments† 65 (37) 143 (64) 274 (76)
Data are number (%) unless stated otherwise. 
CT=computed tomography; GRACE=global registry of acute coronary events; SD=standard deviation.
*Treatment for acute coronary syndrome prescribed during index admission to hospital.
†Primary or secondary prevention treatment started, stopped, or dose altered during index admission to hospital.
Eight participants had CT coronary angiography from which the coronary arteries were not classified as normal, non-obstructive disease, or obstructive 
disease, and these participants have not been included.
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Fig 2 | Cumulative incidence of primary endpoint of one year all cause death or non-
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We recruited intermediate risk patients who were 
found to have a high prevalence of disease (50-75% 
with coronary artery disease) in contrast with the low 
prevalence (<10%) in previous studies.8-11 Moreover, 
recent adoption of high sensitivity troponin testing 
has supported earlier clinical decision making3-7 but 
Table 3 | Primary and key secondary outcomes
CT computed 
angiography and 
standard of care 
(n=877)
Standard of care 
only (n=871) Estimate Hazard ratio (95% CI) P value*
Primary outcome
All cause death or non-fatal 
myocardial infarction (type 1 or 4b)
51 (5.8) 53 (6.1) Unadjusted 0.95 (0.65 to 1.40) 0.79
Adjusted 0.91 (0.62 to 1.35) 0.65
Secondary outcomes 
Death from coronary heart disease or 
non-fatal myocardial infarction
47 (5.4) 45 (5.2) Unadjusted 1.03 (0.69 to 1.55) 0.88
Adjusted 1.02 (0.67 to 1.53) 0.94
Death from cardiovascular disease or 
non-fatal myocardial infarction
48 (5.5) 46 (5.3) Unadjusted 1.03 (0.69 to 1.54) 0.88
Adjusted 1.01 (0.68 to 1.52) 0.95
Non-fatal myocardial infarction 39 (4.4) 40 (4.6) Unadjusted 0.96 (0.62 to 1.50) 0.87
Adjusted 0.95 (0.61 to 1.47) 0.81
Death from coronary heart disease 11 (1.3) 6 (0.7) Unadjusted 1.82 (0.67 to 4.92) 0.24
Adjusted 1.78 (0.66 to 4.82) 0.26
Death from cardiovascular death 12 (1.4) 8 (0.9) Unadjusted 1.49 (0.61 to 3.64) 0.38
Adjusted 1.39 (0.57 to 3.42) 0.47
All cause death 19 (2.2) 17 (2.0) Unadjusted 1.11 (0.58 to 2.13) 0.76
Adjusted 1.03 (0.53 to 1.99) 0.94
Data are number (%) unless stated otherwise. Adjusted hazard ratios are from models adjusting for study site, GRACE (global registry of acute coronary 
events) score, and previous coronary heart disease. 
CT=computed tomography.
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Fig 3 | Prespecified subgroup analyses of one year all cause death or non-fatal myocardial infarction (type 1 or 4b). 
GRACE=global registry of acute coronary events; CTCA=computed tomography coronary angiography
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has misidentified many patients who do not have 
myocardial infarction.24 The strength of CT coronary 
angiography is its high negative predictive value for 
coronary artery disease, which applies to all risk 
groups, including those patients with non-ST segment 
elevation acute coronary syndrome.25 We found that 
40-50% of patients with normal or non-obstructive 
coronary artery disease had raised levels of cardiac 
troponin. Our finding of a 19% relative reduction in the 
hazard for invasive coronary angiography likely reflects 
the exclusion of obstructive coronary artery disease, 
thereby avoiding unnecessary invasive coronary 
angiography, especially in patients with raised levels 
of cardiac troponin not attributable to myocardial 
infarction or obstructive coronary artery disease. 
The reduction in invasive coronary angiography 
was not associated with differences in overall rates 
of coronary revascularisation or clinical events, 
suggesting excellent diagnostic accuracy and 
continued appropriate coronary revascularisation 
for those with obstructive coronary artery disease. 
Also, CT coronary angiography was associated with a 
reduction in the need for further downstream testing 
for ischaemia, underlying its use in diagnosis and the 
associated improved diagnostic certainty reported by 
clinicians.
Table 4 | Medical treatment and other outcomes
CT coronary  angiography 
and standard of care 
(n=877)
Standard of care 
only (n=871) Estimate Odds ratio (95% CI) P value
Inhospital medical treatment for acute 
coronary syndrome
595 (67.8) 580 (66.6) Unadjusted 1.06 (0.87 to 1.29) 0.58
Adjusted 1.06 (0.85 to 1.32) 0.63
Change in preventive treatment 554 (63.2) 539 (61.9) Unadjusted 1.06 (0.87 to 1.28) 0.58
Adjusted 1.07 (0.87 to 1.32) 0.52
Preventive treatment:
 Started 526 (60.0) 509 (58.4) — — —
 Stopped 71 (8.1) 61 (7.0) — — —
 Dose changed 91 (10.4) 100 (11.5) — — —
Participant satisfaction with service 
received:*
— — Unadjusted† 1.23 (1.01 to 1.51) 0.04
Adjusted† 1.25 (1.02 to 1.53) 0.03
 Poor 10 (1.5) 7 (1.1) — — —
 Fair 21 (3.0) 28 (4.5) — — —
 Good 84 (12.2) 92 (14.7) — — —
 Very good 226 (32.8) 215 (34.3) — — —
 Excellent 348 (50.5) 285 (45.5) — — —
Data are number (%) unless stated otherwise. 
CT=computed tomography.
*n=689 for CT coronary angiography and standard of care; n=627 for standard of care only.
†Unadjusted and adjusted odds ratios are from post hoc analysis with proportional odds logistic regression model to estimate the common odds ratio for 
higher levels of satisfaction.
Table 5 | Processes of care outcomes over 12 months
CT coronary angiography 
and standard of care 
(n=877)
Standard of care 
only (n=871) Estimate
Hazard ratio  
(95% CI) P value
Investigations
Invasive coronary angiography 474 (54.0) 530 (60.8) Unadjusted 0.83 (0.74 to 0.94) 0.004
Adjusted 0.81 (0.72 to 0.92) 0.001
Non-invasive coronary artery disease or 
myocardial ischaemia testing (post hoc 
analysis)*
170 (19.4) 228 (26.2) Unadjusted‡ 0.69 (0.56 to 0.84) <0.001
Adjusted‡ 0.66 (0.54 to 0.81) <0.001
Other non-invasive cardiac investigation 
(post hoc analysis)†
470 (53.6) 484 (55.6) Unadjusted 0.95 (0.83 to 1.07) 0.40
Adjusted 0.92 (0.81 to 1.04) 0.19
Coronary revascularisation
Coronary revascularisation 300 (34.2) 288 (33.1) Unadjusted 1.03 (0.88 to 1.22) 0.68
Adjusted 1.03 (0.87 to 1.21) 0.76
Percutaneous coronary intervention 260 (29.6) 240 (27.6) Unadjusted 1.08 (0.90 to 1.28) 0.42
Adjusted 1.08 (0.90 to 1.28) 0.42
Coronary artery bypass graft surgery 52 (5.9) 55 (6.3) Unadjusted 0.94 (0.64 to 1.37) 0.73
Adjusted 0.91 (0.62 to 1.33) 0.63
Recurrent hospital attendance
Re-presentation or recurrent admission to 
hospital with suspected acute coronary 
syndrome or recurrent chest pain
138 (15.7) 130 (14.9) Unadjusted 1.06 (0.83 to 1.34) 0.65
Adjusted 1.06 (0.83 to 1.34) 0.66
Data are number (%) unless stated otherwise. 
CT=computed tomography.
*Stress echocardiogram, stress magnetic resonance imaging, stress nuclear myocardial perfusion imaging, exercise electrocardiogram, cardiac magnetic 
resonance imaging or angiogram, or CT coronary angiogram not as trial intervention. 
†Echocardiogram or electrocardiographic rhythm monitoring. 
‡Evidence of non-proportional hazards was found, and unadjusted and adjusted hazard ratios are reported as estimates indicative of the average effect.
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Comparison with other studies
Previous trials8-10 have used CT coronary angiography 
for early and safe discharge of low risk patients 
from the emergency department. These studies 
were mostly designed to look at length of stay, but 
meta-analyses11  23 indicated that early CT coronary 
angiography was not only associated with shorter 
lengths of stay but also with increased rates of invasive 
angiography and coronary revascularisation. These 
findings were not replicated in a multicentre trial of 500 
low risk patients where rates of coronary angiography, 
revascularisation, and clinical events were unchanged 
by CT coronary angiography.26 Our trial provided data 
for those at higher risk than these previous studies and 
showed that the influence of CT coronary angiography 
was different in this population of patients. We found 
that CT coronary angiography can avoid unnecessary 
coronary angiography without affecting rates of 
coronary revascularisation. For hospitals with no ready 
access to invasive coronary angiography facilities, 
CT coronary angiography could therefore be a useful 
approach to identify those patients who do not require 
transfer to another hospital or further evaluation with 
invasive coronary angiography.
Previous comparisons of early CT coronary 
angiography compared with invasive coronary 
angiography have shown that up to 80% of invasive 
angiography can be avoided in patients with a low 
prevalence of coronary artery disease.27 28 We found 
a more modest reduction in angiography in our trial, 
reflecting the greater prevalence of obstructive coronary 
heart disease in our study population. Also, many 
patients underwent invasive angiography and, for 
these participants, CT coronary angiography increased 
exposure to radiation and contrast, although median 
effective radiation doses were low, and no serious 
adverse reactions were found. Although undertaking 
CT coronary angiography in acutely unwell patients 
can be challenging, we found that more than 90% 
of the CT coronary angiograms were of diagnostic 
quality, comparing favourably with previous studies 
of CT coronary angiography in patients with stable14 
15 and acute chest pain.25 Also, the CT coronary 
angiograms clearly identified those with and without 
obstructive coronary artery disease, and this finding 
is reflected in the differences in the selection of those 
who later underwent invasive coronary angiography 
and coronary revascularisation. Our findings are 
consistent with previous studies25 29 and suggest that 
CT coronary angiography could safely be used as a first 
line investigation where onsite invasive angiography 
is not available or there is a delay in availability, or 
in patients where the clinical diagnosis of myocardial 
infarction is uncertain.
Limitations of the trial
The trial had some limitations. Open trials have the 
potential for bias. By design, however, the primary 
endpoint was assessed by an independent clinical 
endpoint committee who were blinded to group 
allocation. Also, the trial intervention did not affect the 
overall rates of treatment for acute coronary syndrome 
directed by clinicians despite improving diagnostic 
certainty and reducing the use of invasive coronary 
angiography. During the trial, we had to compromise 
on accepting a larger estimate for relative effect size for 
the trial intervention after recalculation of the sample 
size to account for a much lower number of primary 
outcome events and lower recruitment rates than 
anticipated. 
Several reasons could explain why the event rate 
was lower than the original estimate, and likely 
reflects the better diagnostic accuracy of newer high 
sensitive troponin assays and improvements in the 
management of patients in the past decade. Greater 
estimates for relative effect size have been reported 
in previous trials8 10 11 30 although our point estimate 
was similar to a recent meta-analysis,23 which 
indicated a hazard ratio for subsequent myocardial 
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Fig 4 | Cumulative incidence of invasive coronary angiography (top) and coronary 
revascularisation (bottom). One participant in each of the treatment arms had unknown 
date of invasive coronary angiography and one participant in CTCA + standard of care 
arm had unknown date of coronary revascularisation and therefore these participants 
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infarction of 0.88 when CT coronary angiography was 
used in patients with acute chest pain. Although the 
lower confidence boundary of the primary endpoint 
included a clinically meaningful reduction in events, 
the lack of effect on treatment interventions reinforces 
our view that early CT coronary angiography 
is unlikely to influence subsequent myocardial 
infarction, and a larger trial with greater power 
would be unlikely to detect a more modest clinically 
meaningful effect on one year outcomes. Finally, 
longer term follow-up might identify further benefits 
in outcomes, especially if preventive treatments are 
more accurately targeted.
Conclusions
Early CT coronary angiography in intermediate risk 
patients presenting to the emergency department with 
suspected acute coronary syndrome or those with a 
provisional diagnosis of acute coronary syndrome, had 
no effect on the overall treatment and prevention of 
the disease or one year outcomes, and was associated 
with an increase in the length of hospital stay. These 
findings do not support the routine use of early CT 
coronary angiography in intermediate risk patients 
presenting to the emergency department with acute 
chest pain.
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Fig 5 | Cumulative incidence of non-invasive coronary artery disease or myocardial 
ischaemia testing (top) and other non-invasive cardiac investigations (bottom) from 
post hoc analysis. Evidence of non-proportional hazards for non-invasive coronary 
artery disease or myocardial ischaemia testing was found, and adjusted hazard ratio 
was reported as an estimate indicative of the average effect. One participant in CTCA 
+ standard of care arm had unknown date of exercise electrocardiogram and one 
participant in each treatment arm had unknown date of cardiac magnetic resonance 
angiogram and therefore these participants were not included in the time-to-event 
analysis for non-invasive coronary artery disease or myocardial ischaemia testing. 
One participant in standard of care only arm had unknown date of echocardiogram and 
therefore this participant was not included in the time-to-event analysis for other non-
invasive cardiac investigations. CTCA=computed tomography coronary angiography
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